SCHEMBL10043695

SCHEMBL10043695

Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3ccoc3C)ccc1C)c(=O)n2C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 11/20 0.51
NPC1 O15118 9/20 0.51
RAB9A P51151 9/20 0.51
PKM P14618 6/20 0.51
POLB P06746 1/20 0.51
ALDH1A1 P00352 5/20 0.46
TP53 P04637 3/20 0.46
LMNA P02545 3/20 0.46
HSD17B10 Q99714 2/20 0.46
USP2 O75604 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
SYK P43405 1/20 0.43
HTT P42858 3/20 0.42
HPGD P15428 2/20 0.42
STAT1 P42224 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043683 0.87 NPC1 (0.46) SMN1; SMN2NPC1RAB9APKMPOLB
SCHEMBL10043959 0.85 SYK (0.43) SYK
SCHEMBL10043694 0.84 SYK (0.42) POLBLMNASYKRXFP1
SCHEMBL10043705 0.84 MAPT (0.54) SMN1; SMN2NPC1RAB9APOLBALDH1A1
SCHEMBL10043960 0.83 SYK (0.43) NPC1RAB9APOLBALDH1A1LMNA
SCHEMBL10043697 0.83 SYK (0.43) NPC1RAB9APOLBSYKGAA
SCHEMBL10043740 0.83 RAF1 (0.43) SMN1; SMN2RAB9APOLBALDH1A1TP53
SCHEMBL10043673 0.83 SYK (0.46) RAB9APOLBSYK
SCHEMBL10043675 0.83 SYK (0.49) SMN1; SMN2NPC1RAB9APOLBTP53
SCHEMBL10043663 0.83 SYK (0.51) SMN1; SMN2NPC1RAB9APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SMN1; SMN2 2302/4885NPC1 4095/4885RAB9A 1818/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SMN1; SMN2 2302/4885NPC1 4095/4885RAB9A 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.